As of May 29, 2025, Medpace Holdings Inc (MEDP) reports a ROE (Return on Equity) of 48.98%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Medpace Holdings Inc's ROE (Return on Equity)
Over recent years, Medpace Holdings Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 48.98% |
| 2023-12-31 | 50.60% |
| 2022-12-31 | 63.51% |
| 2021-12-31 | 19.08% |
| 2020-12-31 | 18.04% |
This steady improvement highlights how Medpace Holdings Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Medpace Holdings Inc's ROE (Return on Equity) to Peers
To better understand Medpace Holdings Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Medpace Holdings Inc (MEDP) | 48.98% |
| Laxai Pharma Ltd (LAXAF) | 29.97% |
| IQVIA Holdings Inc (IQV) | 22.63% |
| Chromadex Corp (CDXC) | 18.55% |
| PRA Health Sciences Inc (PRAH) | 13.32% |
| Sotera Health Co (SHC) | 10.96% |
Compared to its competitors, Medpace Holdings Inc's ROE (Return on Equity) is higher than all peers, suggesting efficient use of shareholder equity to generate profits.